Access, Ideas, Clarity
A leading virtual platform providing investors with direct access to innovative companies, management teams and thought leaders
What This Means:
This series is designed to provide investors with context to press releases directly from company management teams. It also provides the opportunity for companies to communicate directly to investors and elaborate on recent key news and highlight value driving milestones.
January 8, 2025
Jedd Comiskey, Senior Vice President, Head of Europe, highlights the recent NICE recommendation of LYTENAVA™ (bevacizumab gamma) for the treatment of wet AMD
November 22, 2024
Xenetic Biosciences, Inc. Presents Positive Preclinical Data Highlighting the Potential of Co-Administration of DNase I with CAR T Cells in a Murine Model of Melanoma Lung Metastasis
November 14, 2024
Moleculin Accelerates Planned Unblinded Data Readout for MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial to H2 2025
November 12, 2024
Drs. Pankaj Mohan, CEO of Sonnet, and John Cini, CSO of Sonnet, discuss the Company’s recent issuance of a U.S. patent covering a variant of IL-18 incorporated into two novel immunotherapeutic drug candidates, SON-1400 and SON-1411
October 30, 2024
Dr. Robert Schwartz, Chief Medical Officer of Autonomix discussing additional findings from the 4-6 week follow-up data from the first five “lead-in” patients in the Company’s ongoing proof-of-concept human clinical trial
October 9, 2024
Sonnet BioTherapeutics Inc. Enters into Licensing Agreement with Alkem Laboratories Limited to Develop and Commercialize SON-080 for Diabetic Peripheral Neuropathy (DPN) in India
September 16, 2024
Wally Klemp, CEO of Moleculin, discusses the Company’s recent update on the Phase 2 clinical trial of STAT3 inhibitor in combination with radiation for the treatment of glioblastoma
_Logo_HOR.png){kind=logo}
July 31, 2024
Mitch Jones, MD, PhD, CMO of Palisade Bio highlights recent findings from a microbiome study confirming local bioactivation of lead product candidate, PALI-2108
July 24, 2024
Sonnet BioTherapeutics Reports Encouraging Data from Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) That Support Advancement into Phase 2 Study
July 18, 2024
Brad Hauser, Chief Executive Officer of Autonomix, discusses the Company’s agreement to license FDA-cleared ablation technology from RF Innovations, Inc.
July 11, 2024
Marc Hertz, PhD, CEO of GRI Bio underscores importance of the interim data from their ongoing Phase 2a biomarker study for Idiopathic Pulmonary Fibrosis (IPF)
_Logo_HOR.png){kind=logo}
July 3, 2024
Preliminary Positive Results from the First Five “Lead-in” Patients in the Company’s Ongoing Human Clinical Trial
July 1, 2024
Palisade Bio’s Lead Product Candidate PALI-2018 Demonstrates Positive Preclinical Data
May 22, 2024
Positive Data from Idiopathic Pulmonary Fibrosis (IPF) and Systemic Lupus Erythematosus (SLE) Programs
April 25, 2024
The Annamycin Opportunity
May 23, 2024
Autonomix Preclinical Study Successfully Demonstrates That Nerve Ablation Can Slow Tumor Metastasis in Pancreatic Cancer
April 25, 2024
March 15, 2024
ReElement Technologies' Certificate of Occupancy for Marion, Indiana Critical Mineral Refining Supersite
Positive Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical’s VenoValve® Pivotal Trial
February 29, 2024
A Major Inflection Point - The Moleculin Opportunity in 2024 and Beyond Series (Part 3 of 3)
February 15, 2024
February 22, 2024
A Major Inflection Point - The Moleculin Opportunity in 2024 and Beyond Series (Part 2 of 3)
A Major Inflection Point - The Moleculin Opportunity in 2024 and Beyond Series (Part 1 of 3)
February 12, 2024
Xenetic Biosciences Highlights Encouraging Recently Reported Preclinical Data on Innovative DNase I Oncology Platform
January 31, 2024
$8,000,000 Transaction for Exclusive Worldwide Rights to Technology for Cardiology Field Use –
Over 100 patents in portfolio
February 09, 2024
AIM ImmunoTech Reports Positive Topline Results from Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions
_Logo_HOR.png){kind=logo}
January 29, 2024
Palisade Bio Reports Positive Preclinical Data of Lead Program PALI-2108 at the 2024 Crohn's & Colitis Congress
January 9, 2024
American Resources Corporation's ReElement Technologies Adds Former United States Ambassador Mark Gilbert to Board of Directors
January 4, 2024
Morphogenesis, Inc. Announces Corporate Rebranding to TuHURA Biosciences, Inc. and Provides a
Business Overview
January 3, 2024
American Resources Corporation's ReElement Technologies Adds Former CIA Senior Executive Kevin Higgins to Board of Directors
December 17, 2024
Reid Bissonnette, Ph.D, Executive Consultant for Translational Research and Development at Xenetic, discusses extension of its Research Agreement with the University of Virgina
December 9, 2024
Sonnet BioTherapeutics Announces Topline Safety Data Following Successful Completion of SON-1010 Monotherapy Dose Escalation in Phase 1 SB101 Trial
December 4, 2024
Sonnet BioTherapeutics Announces Publication Detailing the Discovery and Development of SON-1010, an Albumin-Binding IL-12 Fusion Protein, Demonstrating Its Mechanism of Action